BR112018072468A2 - composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêutica - Google Patents
composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêuticaInfo
- Publication number
- BR112018072468A2 BR112018072468A2 BR112018072468-8A BR112018072468A BR112018072468A2 BR 112018072468 A2 BR112018072468 A2 BR 112018072468A2 BR 112018072468 A BR112018072468 A BR 112018072468A BR 112018072468 A2 BR112018072468 A2 BR 112018072468A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- compound
- stereoisomer
- protein kinase
- oxide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 102000001253 Protein Kinase Human genes 0.000 title abstract 4
- 108060006633 protein kinase Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000012453 solvate Substances 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000893 fibroproliferative effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
a presente invenção refere-se a um composto adequado para uso como um inibidor de quinase de acordo com a fórmula geral (i) [composto (c), doravante], ou o n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero do mesmo, fórmula (i) em que a, r1, r2, r3, r3?, r4, r4?, x, y, z, t são conforme definido nas reivindicações. a invenção se refere adicionalmente a um método in vitro para inibir atividade de proteína quinase que compreende colocar uma proteína quinase em contato com um composto de fórmula (i), ou o n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero do mesmo. a invenção se refere adicionalmente aos compostos de fórmula (i) por si, assim como a seu uso como um medicamento, e para uso ou em um método de tratamento de uma doença mediada por uma proteína quinase selecionada a partir de câncer, distúrbios inflamatórios, doenças cardiovasculares, doenças induzidas por vírus, doenças circulatórias, doenças fibroproliferativas e distúrbios de sensibilização à dor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305530 | 2016-05-04 | ||
| EP16305530.4 | 2016-05-04 | ||
| PCT/EP2017/060730 WO2017191297A1 (en) | 2016-05-04 | 2017-05-04 | Adenine derivatives as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018072468A2 true BR112018072468A2 (pt) | 2019-02-19 |
Family
ID=55953089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018072468-8A BR112018072468A2 (pt) | 2016-05-04 | 2017-05-04 | composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11236093B2 (pt) |
| EP (1) | EP3452477B1 (pt) |
| KR (1) | KR102479746B1 (pt) |
| CN (1) | CN109311882B (pt) |
| AU (1) | AU2017260298B9 (pt) |
| BR (1) | BR112018072468A2 (pt) |
| CA (1) | CA3022896A1 (pt) |
| EA (1) | EA201892460A1 (pt) |
| IL (1) | IL262700B (pt) |
| MX (1) | MX2018013325A (pt) |
| SG (1) | SG11201809674QA (pt) |
| WO (1) | WO2017191297A1 (pt) |
| ZA (1) | ZA201808014B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018019681A1 (en) * | 2016-07-25 | 2018-02-01 | Nerviano Medical Sciences S.R.L. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| US20210147405A1 (en) * | 2017-06-14 | 2021-05-20 | European Molecular Biology Laboratory | Bicyclic heteroaromatic urea or carbamate compounds for use in therapy |
| WO2020221334A1 (en) * | 2019-04-30 | 2020-11-05 | City University Of Hong Kong | Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof |
| EP4006028A4 (en) | 2019-07-26 | 2022-09-14 | Zhuhai Yufan Biotechnologies Co., Ltd | IRAK4 KINASE INHIBITOR AND METHOD FOR PREPARING IT |
| CN111560389B (zh) * | 2020-06-11 | 2022-07-01 | 云南中烟工业有限责任公司 | 烟草丝裂原活化蛋白激酶基因NtMAPK8及其应用 |
| AU2022292554A1 (en) | 2021-06-14 | 2024-01-04 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9010404D0 (en) | 1990-05-09 | 1990-06-27 | Pfizer Ltd | Therapeutic agents |
| FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| WO2005009348A2 (en) | 2003-06-25 | 2005-02-03 | Ariad Pharmaceuticals, Inc. | Substituted purine derivatives |
| WO2005117882A2 (en) * | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US20120034250A1 (en) | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2014077784A1 (en) | 2012-11-19 | 2014-05-22 | Agency For Science, Technology And Research | Method of treating cancer |
| WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
-
2017
- 2017-05-04 BR BR112018072468-8A patent/BR112018072468A2/pt active Search and Examination
- 2017-05-04 CA CA3022896A patent/CA3022896A1/en active Pending
- 2017-05-04 MX MX2018013325A patent/MX2018013325A/es unknown
- 2017-05-04 SG SG11201809674QA patent/SG11201809674QA/en unknown
- 2017-05-04 CN CN201780033173.5A patent/CN109311882B/zh active Active
- 2017-05-04 US US16/097,805 patent/US11236093B2/en active Active
- 2017-05-04 WO PCT/EP2017/060730 patent/WO2017191297A1/en active Search and Examination
- 2017-05-04 EA EA201892460A patent/EA201892460A1/ru unknown
- 2017-05-04 AU AU2017260298A patent/AU2017260298B9/en active Active
- 2017-05-04 KR KR1020187034306A patent/KR102479746B1/ko active IP Right Grant
- 2017-05-04 EP EP17722013.4A patent/EP3452477B1/en active Active
-
2018
- 2018-10-31 IL IL262700A patent/IL262700B/en unknown
- 2018-11-27 ZA ZA2018/08014A patent/ZA201808014B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109311882A (zh) | 2019-02-05 |
| MX2018013325A (es) | 2019-08-16 |
| IL262700A (en) | 2018-12-31 |
| KR102479746B1 (ko) | 2022-12-21 |
| EA201892460A1 (ru) | 2019-09-30 |
| CA3022896A1 (en) | 2017-11-09 |
| SG11201809674QA (en) | 2018-11-29 |
| ZA201808014B (en) | 2020-02-26 |
| US11236093B2 (en) | 2022-02-01 |
| KR20190003968A (ko) | 2019-01-10 |
| JP2019516688A (ja) | 2019-06-20 |
| AU2017260298B9 (en) | 2021-09-30 |
| EP3452477B1 (en) | 2023-09-13 |
| IL262700B (en) | 2022-02-01 |
| AU2017260298B2 (en) | 2021-09-02 |
| US20190127379A1 (en) | 2019-05-02 |
| EP3452477C0 (en) | 2023-09-13 |
| AU2017260298A1 (en) | 2018-12-13 |
| WO2017191297A1 (en) | 2017-11-09 |
| CN109311882B (zh) | 2022-02-11 |
| EP3452477A1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018072468A2 (pt) | composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêutica | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| BR112022010383A2 (pt) | Compostos tricíclicos substituídos | |
| BR112017024933A8 (pt) | Alvocidib produce com a bioavailabilidade aumentada | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112019022512A2 (pt) | Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats | |
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| BR112015012454A8 (pt) | compostos inibidores de atr quinase, seu uso, composição farmacêutica compreendendo os mesmos, seus intermediários e método de preparação | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| BR112018007772A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
| EA201000341A1 (ru) | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112015015635A8 (pt) | composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão | |
| BR112016028273A8 (pt) | derivados radiorrotulados de composto de 2-amino6-fluoro-n-[5-fluoro-piridin-3-il]-pirazol[1,5-a]pirimidin3-carboxamida úteis como inibidor de atr cinase, processo para preparação do referido composto, bem como diferentes formas sólidas do mesmo, uso destas, e composição farmacêutica | |
| ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren | |
| BR112012027062A2 (pt) | composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica | |
| MX2018016419A (es) | Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida. | |
| BR112014023384A8 (pt) | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |